Investigation of resveratrol as a xanthine oxidase inhibitor: Mechanistic insights and therapeutic implications for gout and hyperuricemia

被引:0
|
作者
Chen, Jianmin [1 ,2 ,3 ]
Chen, Juan [1 ]
Feng, Baozhu [1 ]
Ning, Meilian [1 ]
Wu, Wanhui [1 ]
Zou, Shiqi [1 ]
机构
[1] Putian Univ, Sch Pharm, Putian 351100, Fujian, Peoples R China
[2] Putian Univ, Fujian Prov Univ, Key Lab Pharmaceut Anal, Putian, Fujian, Peoples R China
[3] Putian Univ, Fujian Prov Univ, Lab Med, Putian, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
allopurinol; hyperuricemia; resveratrol; uric acid; xanthine oxidase; URIC-ACID; IN-VITRO; OXIDOREDUCTASE; TOPIROXOSTAT; TYROSINASE;
D O I
10.1002/bab.2690
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gout predominantly stems from hyperuricemia, precipitating the accumulation of urate crystals and consequent joint inflammation, swelling, and pain, thereby compromising the quality of life and presenting a formidable medical dilemma. Although conventional treatments like allopurinol and febuxostat target uric acid reduction via xanthine oxidase (XO) inhibition, they often entail adverse effects, prompting the exploration of safer alternatives. Resveratrol, a polyphenolic compound abundant in fruits and vegetables, has emerged as a potential XO inhibitor. However, its precise inhibitory mechanisms remain poorly understood. This study aims to comprehensively investigate resveratrol's XO inhibition through mechanistic insights, molecular docking simulations, animal model experiments, and biochemical analysis, contributing valuable insights to the development of novel therapeutics for hyperuricemia and gout.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout
    Nishino, Takeshi
    Okamoto, Ken
    JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2015, 20 (02): : 195 - 207
  • [2] Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout
    Takeshi Nishino
    Ken Okamoto
    JBIC Journal of Biological Inorganic Chemistry, 2015, 20 : 195 - 207
  • [3] Febuxostat: A Novel Non-Purine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Gout
    Yu, Kuang-Hui
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 69 - 75
  • [4] 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: A potential therapeutic agent for treatment of hyperuricemia and gout
    Lue, Jian-Ming
    Yao, Qizhi
    Chen, Changyi
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (09) : 1328 - 1337
  • [5] Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout
    Bruce, Susan P.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (12) : 2187 - 2194
  • [6] Febuxostat: A Selective Xanthine-Oxidase/Xanthine-Dehydrogenase Inhibitor for the Management of Hyperuricemia in Adults With Gout
    Ernst, Michael E.
    Fravel, Michelle A.
    CLINICAL THERAPEUTICS, 2009, 31 (11) : 2503 - 2518
  • [7] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Matsuo, Hiroshi
    Ishikawa, Eiji
    Machida, Hirofumi
    Mizutani, Yasuhide
    Tanoue, Akiko
    Ohnishi, Takahiro
    Murata, Tomohiro
    Okamoto, Shinya
    Ogura, Toru
    Nishimura, Yuki
    Ito, Hiroo
    Yasutomi, Masashi
    Katayama, Kan
    Nomura, Shinsuke
    Ito, Masaaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (04) : 307 - 313
  • [8] Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies
    Saag, Kenneth G.
    Dalbeth, Nicola
    Hsu, Chi-yuan
    Kuo, Chang-Fu
    Nuki, George
    Perez-Ruiz, Fernando
    White, William B.
    Hariri, Ali
    Lee, Yunjung
    Jang, Younghwan
    Han, Song
    Choi, Hyon K.
    CONTEMPORARY CLINICAL TRIALS, 2025, 151
  • [9] Hyperuricemia Resistant to a Xanthine Oxidase Inhibitor, Topiroxostat: a Case Report
    Takahide Kimura
    Seiki Yamada
    Masayuki Tanemoto
    SN Comprehensive Clinical Medicine, 4 (1)
  • [10] Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout
    Huneycutt, Emily
    Board, Chase
    Clements, Jennifer N.
    JOURNAL OF PHARMACY PRACTICE, 2018, 31 (06) : 670 - 677